Larvol Delta - aTyr-Pharma-Announces-Phase-2-Study-of-ATYR1923-in-COVID19-Patients-with-Severe-Respiratory-Complications-Following-FDA-Acceptance-of-IND-Application

Stalaris (ATYR1923) - aTyr Pharma, Kyorin

http://www.globenewswire.com/news-release/2020/04/21/2019306/0/en/aTyr-Pharma-Announces-Phase-2-Study-of-ATYR1923-in-COVID-19-Patients-with-Severe-Respiratory-Complications-Following-FDA-Acceptance-of-IND-Application.html

Apr 21, 2020

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next